Fidanacogene Elaparvovec-dzkt (Beqvez) — CPB 1060 | AETNA Coverage Update

Aetna modified CPB 1060 for fidanacogene elaparvovec-dzkt (Beqvez), effective September 26, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated CPB 1060 — the coverage policy governing fidanacogene elaparvovec-dzkt (Beqvez), the gene therapy for hemophilia B. The primary billing code is HCPCS J1414 (injection, fidanacogene elaparvovec-dzkt, per therapeutic dose), and this update carries two hard requirements that will drive claim denials if your team misses them: mandatory precertification and GCIT Network site-of-care rules. This is a high-exposure policy. A single infusion claim can run into seven figures, so getting the precertification and place-of-service details right before September 26, 2025 is not optional.

Quick-Reference Table

Aetna Fidanacogene Elaparvovec-dzkt Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Beqvez coverage policy applies to commercial medical plans. Medicare members have a separate pathway — you'll need to check the Medicare Part B criteria directly on Aetna's site.

The core medical necessity question here centers on hereditary factor IX deficiency, coded D67. That's the primary ICD-10 diagnosis driving coverage for J1414. The policy also references a broad set of supporting diagnosis codes — liver function indicators, coagulopathy (D68.8), and hepatic fibrosis markers like K74.02 — which reflect the monitoring and safety profile requirements built into Beqvez's administration protocol.

Prior authorization is mandatory. Every Aetna participating provider must get precertification before administering Beqvez. Call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity (SMN) forms, access the Specialty Pharmacy Precertification forms on Aetna's provider portal. Don't assume a prior auth for factor IX replacement products (J7193–J7203) transfers — this is a separate process for the gene therapy itself.

Aetna prior authorization requirements for Beqvez are non-negotiable on this policy. Claims submitted without precertification will deny. Given the cost of a single therapeutic dose, a denial here is not a minor inconvenience — it's a serious revenue cycle event.

Coverage Indications at a Glance

Aetna Fidanacogene Elaparvovec-dzkt Billing Guidelines and Action Items 2025

1. Submit precertification before September 26, 2025 for any pending cases.
If you have patients in the pipeline for Beqvez, start the precertification process now. Call (866) 752-7021. Do not wait until the infusion date. Retroactive authorization for gene therapy is extremely difficult to get.

2. Confirm your infusion site is a GCIT Network facility.
Aetna requires Beqvez to be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) designated facility — unless the member's plan has specifically waived this requirement. Check the Aetna Institutes GCIT Designated Networks list before scheduling. Administering at a non-designated site will trigger a claim denial regardless of clinical criteria.

3. Build out your charge capture to include the full monitoring code set.
This policy covers a significant set of lab and monitoring CPT codes alongside the J1414 infusion. That includes liver function panels (CPT 82247, 82248, 82977, 84075, 84450, 84460), coagulation studies (CPT 85250, 85335, 85610), complete blood counts (CPT 85018, 85049), and renal function (CPT 82565, 82570). Add CPT 91200 for liver elastography and CPT 76705 for limited abdominal ultrasound. These are legitimate, billable services tied directly to the Beqvez protocol — make sure your charge capture picks them up.

4. Link your diagnosis codes precisely.
D67 (hereditary factor IX deficiency) is your primary diagnosis for J1414 reimbursement. Liver-related codes like K74.02, K74.60–K74.68, and hepatitis codes B16.x–B18.x are supporting diagnoses that reflect why certain patients may or may not qualify. Don't attach hepatitis or cirrhosis codes to the J1414 claim line unless they're genuinely active conditions — that will create a medical necessity problem, not solve one.

5. Don't swap J1414 for factor IX replacement codes.
J7193, J7194, J7195, J7200, J7201, J7202, J7203, and J7213 are listed in this policy as "other HCPCS codes related to the CPB." These are conventional factor IX replacement products — not interchangeable with the gene therapy. If a patient is transitioning from prophylactic factor IX replacement to Beqvez, the billing pathway changes completely. Make sure your team understands the distinction before submitting.

6. Use infusion administration codes correctly.
Beqvez is administered via IV infusion. Bill CPT 96365 for the initial hour, CPT 96366 for each additional hour, CPT 96367 for additional sequential infusion (different drug), and CPT 96368 for concurrent infusion. Infusion billing for Beqvez must follow standard infusion hierarchy rules. The GCIT facility typically bills these — confirm who holds the billing responsibility before the date of service.

7. If your patient's plan design waives the GCIT requirement, document it.
The policy explicitly allows plan designs to opt out of the GCIT Network requirement. If a member's plan has waived it, document that in the file before submitting. Absent that documentation, Aetna will default to the GCIT requirement, and you will not win that appeal based on a verbal understanding.

If you're not sure how this applies to your patient mix or your facility's GCIT status, talk to your compliance officer before the effective date of September 26, 2025.

CPT, HCPCS, and ICD-10 Codes for Fidanacogene Elaparvovec-dzkt Under CPB 1060

HCPCS Code Covered When Selection Criteria Are Met

Other HCPCS Codes Related to CPB 1060 (Factor IX Replacement Products)

CPT Codes Related to CPB 1060

Key ICD-10-CM Diagnosis Codes

The real issue here is that Beqvez billing sits at the intersection of gene therapy, specialty infusion, and hepatology monitoring — three areas with their own billing guidelines and site-of-care rules. The coverage policy is clear on precertification and GCIT requirements, but the monitoring code set is where most billing teams will leave money on the table. Capture every CPT code tied to the treatment protocol. They're covered. Bill them.